| Outcome Measures: |
Primary: Safety and tolerability of single and multiple ascending doses of VS 105 administered orally to healthy and HD subjects (numbers and percentages of adverse events)., Adverse events will be counted within each treatment and study part. The numbers and percentages of adverse events will be tabulated by body system, preferred term, and severity., 3 weeks|Pharmacokinetic (PK) of VS-105 in serum: area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration, AUC0-last: The area under the serum concentration-time curve from time zero to the time of the last quantifiable concentration., pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.|PK of VS-105 in serum: area under the serum concentration-time curve from time zero to infinity., AUC0-∞: The area under the serum concentration-time curve from time zero to infinity, pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.|PK of VS-105 in serum: observed maximum serum concentration following drug administration, Cmax: The observed maximum serum concentration following drug administration, pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.|PK of VS-105 in serum: terminal elimination half-life, T1/2: The terminal elimination half-life, pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing.|PK of VS-105 in serum: time to reach the maximum concentration after drug administration, Tmax: The time to reach the maximum concentration after drug administration, pre-dose and 0.5, 1, 1.5, 2, 4, 6, 8, 10, 12 and 16 hours and 2, 3, 7, 8, 9, 14, 15, 16 days after dosing. | Secondary: Serum calcium (ionized) in healthy and HD subjects, To evaluate the changes from baseline in concentrations of serum calcium (ionized) in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only)., Pre-dose and 1, 2, 15, 21 days after dosing|Serum phosphorous in healthy and HD subjects, To evaluate the changes from baseline in concentrations of serum phosphorous in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only)., Pre-dose and 1, 2, 15, 21 days after dosing|Serum intact parathyroid hormone (iPTH) in healthy and HD subjects, To evaluate the changes from baseline in concentrations of serum intact parathyroid hormone (iPTH) in healthy and HD subjects after multiple doses of VS 105 (Part 2 and Part 3 only)., Pre-dose and 1, 2, 15, 21 days after dosing
|
